Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:CGTX NASDAQ:GBIO NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$8.72-7.7%$9.24$3.75▼$11.54$152.72M2.7162,603 shs44,399 shsCGTXCognition Therapeutics$1.61+4.5%$1.47$0.22▼$3.83$113.23M1.337.83 million shs5.10 million shsGBIOGeneration Bio$5.95+6.4%$5.24$3.00▼$29.10$37.65M2.4874,325 shs173,074 shsNVCTNuvectis Pharma$6.21+0.3%$6.95$4.44▼$11.80$157.58M-0.2759,935 shs33,178 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-7.72%-10.84%+9.00%-2.46%+871,999,900.00%CGTXCognition Therapeutics+4.55%-36.36%+4.55%+475.00%+170.59%GBIOGeneration Bio+6.44%-3.25%-5.41%+65.28%-76.10%NVCTNuvectis Pharma+0.32%-2.05%-3.42%-22.86%-2.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$8.72-7.7%$9.24$3.75▼$11.54$152.72M2.7162,603 shs44,399 shsCGTXCognition Therapeutics$1.61+4.5%$1.47$0.22▼$3.83$113.23M1.337.83 million shs5.10 million shsGBIOGeneration Bio$5.95+6.4%$5.24$3.00▼$29.10$37.65M2.4874,325 shs173,074 shsNVCTNuvectis Pharma$6.21+0.3%$6.95$4.44▼$11.80$157.58M-0.2759,935 shs33,178 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-7.72%-10.84%+9.00%-2.46%+871,999,900.00%CGTXCognition Therapeutics+4.55%-36.36%+4.55%+475.00%+170.59%GBIOGeneration Bio+6.44%-3.25%-5.41%+65.28%-76.10%NVCTNuvectis Pharma+0.32%-2.05%-3.42%-22.86%-2.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00129.36% UpsideCGTXCognition Therapeutics 3.25Buy$2.8375.98% UpsideGBIOGeneration Bio 2.67Moderate Buy$10.6779.27% UpsideNVCTNuvectis Pharma 3.00Buy$15.33146.91% UpsideCurrent Analyst Ratings BreakdownLatest GBIO, CGTX, ACOG, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/13/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $7.008/13/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/4/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $10.007/18/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$50.00 ➝ $70.006/26/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/AGBIOGeneration Bio$19.89M2.02N/AN/A$12.91 per share0.46NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.60N/A∞N/AN/A-80.16%-60.95%11/13/2025 (Estimated)CGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)GBIOGeneration Bio-$131.67M-$10.82N/AN/AN/A-341.12%-91.07%-33.65%11/5/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)Latest GBIO, CGTX, ACOG, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACOGAlpha Cognition-$0.46-$0.65-$0.19-$0.65$2.32 million$1.66 million8/12/2025Q2 2025GBIOGeneration Bio-$2.80-$3.12-$0.32-$3.12$2.51 million$0.77 million8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83CGTXCognition TherapeuticsN/A1.541.54GBIOGeneration BioN/A7.517.51NVCTNuvectis PharmaN/A2.662.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/ACGTXCognition Therapeutics43.35%GBIOGeneration Bio95.22%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%CGTXCognition Therapeutics14.40%GBIOGeneration Bio21.10%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.16 million13.90 millionN/ACGTXCognition Therapeutics2073.52 million62.94 millionNot OptionableGBIOGeneration Bio1506.74 million5.31 millionOptionableNVCTNuvectis Pharma825.46 million17.69 millionNot OptionableGBIO, CGTX, ACOG, and NVCT HeadlinesRecent News About These CompaniesNuvectis Pharma, Inc. to Participate in H.C. Wainwright Global Investment Conference with On-Demand Presentation and Virtual MeetingsSeptember 4, 2025 | quiverquant.comQNuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comNuvectis Pharma, Inc.August 26, 2025 | cnn.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest UpdateAugust 18, 2025 | marketbeat.comNuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900August 12, 2025 | finanznachrichten.deNuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900August 11, 2025 | globenewswire.comNuvectis (NVCT) Q2 Loss Widens 43%August 5, 2025 | fool.comNuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 5, 2025 | globenewswire.comNuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation StudyJuly 31, 2025 | globenewswire.comNuvectis Pharma Insiders Added US$2.50m Of Stock To Their HoldingsJuly 29, 2025 | finance.yahoo.comNuvectis Pharma Inc News (NVCT) - Investing.comJuly 18, 2025 | investing.comNuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading TherapiesJuly 8, 2025 | finance.yahoo.comMarlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockJune 25, 2025 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 5,399 Shares of StockJune 21, 2025 | insidertrades.comInsiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchasesJune 18, 2025 | finance.yahoo.comNuvectis Pharma: Still Interesting, But Still Too Risky To Jump InJune 18, 2025 | seekingalpha.comNuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2025 | globenewswire.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 SharesMay 14, 2025 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases 2,650 Shares of StockMay 10, 2025 | insidertrades.comDoes Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?May 9, 2025 | zacks.comNuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth PlansMay 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGBIO, CGTX, ACOG, and NVCT Company DescriptionsAlpha Cognition NASDAQ:ACOG$8.72 -0.73 (-7.72%) As of 09/16/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Cognition Therapeutics NASDAQ:CGTX$1.61 +0.07 (+4.55%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.66 +0.05 (+2.86%) As of 09/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Generation Bio NASDAQ:GBIO$5.95 +0.36 (+6.44%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$5.77 -0.18 (-3.03%) As of 09/16/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Nuvectis Pharma NASDAQ:NVCT$6.21 +0.02 (+0.32%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$6.22 +0.00 (+0.08%) As of 09/16/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
